MarginsXMarginsX
Home › Markets › Health Care › SABS

SAB Biotherapeutics Inc. (SABS)

SABS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.00
+1.35% on the day
Market cap
$270.3M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
$13.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/0001833214-26-000003-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSABS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001833214
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income$13.3M
Operating income-$49.0M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$10.5M
Total assets$172.8M
P/E (computed)20.4×
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
3.2 months
$14.4M cash at September 30, 2026
Share count, 1 year
+89.2%
2025-11-10 to 2026-11-02 · +1621.9% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$14.4M cash; operating cash flow -$13.5M a quarter.Report 2026-09-30
Shares outstanding90,088,831 (2026-11-02); 47,606,851 a year earlier; 52,319,156 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-10 on 2024-01-05Source 2024-01-05
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-03-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-10-22
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$22.3M-$13.0M$14.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$22.5M-$9.8M$8.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$18.9M-$14.3M$20.5MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$16.9M-$16.8M$10.5M$0$010-K 2026-03-09
Q3 2025
2025-09-30
Not filed$45.4M-$13.0M$29.4M$0Needs four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$10.1M-$7.2M$3.7M$0Needs four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$5.2M-$7.8M$5.6M$139KNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
$115K-$11.4M-$9.5M$8.9M$552K$1.3M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-08-21
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-10-13
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 436 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.3%
1 month+10.4%
3 months-21.1%
Year to date-20.9%
1 year-4.5%
From 52-week high-35.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LXEOLexeo Therapeutics Inc.$3.23+12.54%$265.0M
DTILPrecision BioSciences Inc.$7.28-3.77%$277.6M
OCGNOcugen Inc.$0.7730-6.62%$262.3M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M
AGENAgenus Inc.$6.29-6.54%$284.6M
PLXProtalix BioTherapeutics Inc. (DE)$3.03-0.66%$255.5M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier